Title : Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy.

Pub. Date : 2020 Jan

PMID : 31691525






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Circulating plasma lncRNAs as novel markers of EGFR mutation status and monitors of epidermal growth factor receptor-tyrosine kinase inhibitor therapy. Tyrosine epidermal growth factor receptor Homo sapiens
2 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens
3 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens
4 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens
5 BACKGROUND: Epidermal growth factor receptor (EGFR) gene mutations predict tumor response to EGFR tyrosine kinase inhibitors (EGFR-TKIs) in non-small cell lung cancer (NSCLC). Tyrosine epidermal growth factor receptor Homo sapiens